180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California. The company went IPO on 2017-06-07. This strategy is built for the community, by the community. Through its partnership with Electric Capital, ETHZilla's treasury strategy aims to pursue a differentiated yield generation program meant to outperform traditional ETH staking. The firm has also been evolving its business towards software-enabled gaming and entertainment. In addition to its ETH treasury strategy, the Company continues to maintain and accelerate the deployment and development of its gaming initiatives.
Follow-Up Questions
ETHZilla Corp のCEOは誰ですか？
Mr. McAndrew Rudisill は ETHZilla Corp の Chairman で、2025 から在籍しています。
